Sodium–glucose transport: role in diabetes mellitus and potential clinical implications
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: Current options for glycemic control are less than optimal in terms of efficacy and to reduce complications in the diabetic population. Selective inhibition of SGLT2 in the proximal tubule increases urinary glucose excretion thereby reducing plasma glucose levels, which may present a novel therapeutic approach. RECENT FINDINGS: SGLT2 inhibitors enhance glucose excretion and improve glycemic control in patients with type 2 diabetes in the absence of clinically relevant hypoglycemia or sustained changes in volume status or glomerular filtration rate. This is associated with lowering of body weight and may reduce systolic blood pressure. The increased glucosuria appears to increase the risk of genital infections but may not increase the risk of urinary tract infections. SUMMARY: The ability of SGLT2 inhibitors to reduce plasma glucose without inducing increased insulin secretion, clinically relevant hypoglycemia, or weight gain constitutes a major advance. The ability to increase glucose excretion provides a powerful means to treat caloric excess conditions. Important questions remain to be resolved and more clinical research is needed on the long-term effects of SGLT2 inhibition. Potential extrarenal effects need to be explored in order to determine the safety of these compounds. It also remains to be determined whether these drugs lower the toxicity of glucose directly on renal cells, independent of hyperglycemia, which may slow or prevent the progressive nature of diabetic nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins
Wood, I. S., & Trayhurn, P. (2003) · British Journal of Nutrition · doi:10.1079/bjn2002763 · Cited by 889
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698
Meng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701272q · Cited by 634
Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
Komoroski, B., Vachharajani, N., Boulton, D., Kornhauser, D., Geraldes, M., Li, L., & Pfister, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.251 · Cited by 350
Cited by
Gorboulev, V., Schürmann, A., Vallon, V., Kipp, H., Jaschke, A., Klessen, D., Friedrich, A., Scherneck, S., Rieg, T., Cunard, R., et al. (2012) · Diabetes · doi:10.2337/db11-1029 · Cited by 687
Self-citationVallon, V., Gerasimova, M., Rose, M. A., Masuda, T., Satriano, J., Mayoux, E., Koepsell, H., Thomson, S. C., & Rieg, T. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00520.2013 · Cited by 483
“Pharmacological inhibition of the renal sodium-glucose 54 cotransporter SGLT2 (SLC5A2) is a new approach that inhibits the renal reabsorption of filtered 55 glucose thereby lowering blood glucose levels without increasing body weight (6; 17; 40).”
BackgroundResultSelf-citationThe proximal tubule in the pathophysiology of the diabetic kidney
Vallon, V. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00809.2010 · Cited by 395
Self-citationVallon, V., & Thomson, S. C. (2012) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020911-153333 · Cited by 376
“Selective inhibitors of SGLT2 are currently in clinical trials to inhibit renal glucose reabsorption and to increase renal excretion, thereby lowering hyperglycemia (14, 15).”
BackgroundSelf-citationVallon, V., Rose, M., Gerasimova, M., Satriano, J., Platt, K. A., Koepsell, H., Cunard, R., Sharma, K., Thomson, S. C., & Rieg, T. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00409.2012 · Cited by 370
Self-citationRieg, T., Masuda, T., Gerasimova, M., Mayoux, E., Platt, K., Powell, D. R., Thomson, S. C., Koepsell, H., & Vallon, V. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00518.2013 · Cited by 310
Self-citationMusso, G., Gambino, R., Cassader, M., & Pagano, G. (2012) · Annals of Medicine · doi:10.3109/07853890.2011.560181 · Cited by 287
Panchapakesan, U., Pegg, K., Gross, S., Komala, M. G., Mudaliar, H., Forbes, J., Pollock, C., & Mather, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054442 · Cited by 277
Pathophysiology of the Diabetic Kidney
Vallon, V., & Komers, R. (2011) · Comprehensive Physiology · doi:10.1002/cphy.c100049 · Cited by 259
Self-citationSodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus
Song, P., Onishi, A., Koepsell, H., & Vallon, V. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1168808 · Cited by 194
“through the basolateral membrane by the facilitative GLUTs – GLUT2 and GLUT1.[5,126] As demonstrated in mice, rats, and humans, SGLT2 is expressed in the early part of the proximal tubules (S1/S2 segments), whereas SGLT1 is expressed in the more distal part (S2/S3 segments) of the proximal tubules [17,28,41] (Figure 2…”
BackgroundSelf-citationMitochondrial dysfunction and complications associated with diabetes
Blake, R., & Trounce, I. A. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.11.007 · Cited by 190
The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors
Cangoz, S., Chang, Y.-Y., Chempakaseril, S. J., Guduru, R. C., Huynh, L. M., John, J. S., John, S. T., Joseph, M. E., Judge, R., Kimmey, R., et al. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12077 · Cited by 35
Metadata
- Authors
- Vallon, V., & Sharma, K.
- Venue
- Current Opinion in Nephrology and Hypertension
- Published
- 2010-09
- Volume
- 19
- Issue
- 5
- Pages
- 425-431
- ISSN
- 1062-4821 (ISSN-L)
- OpenAlex
- W1978796367
- Cited by
- 57
- References
- 5
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.